Beta

Inovio pharmaceuticals, inc.INO.US Overview

US StockHealthcare
(No presentation for INO)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

INO AI Insights

INO Overall Performance

INO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

INO Recent Performance

-1.39%

Inovio pharmaceuticals, inc.

-1.64%

Avg of Sector

-0.21%

S&P500

INO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check INO's Trend

INO Key Information

INO Valuation Metrics

INO Profile

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Price of INO

INO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

INO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.59
PE Ratio (TTM)
-
Forward PE
16.58
PS Ratio (TTM)
1435.97
PB Ratio
3.86
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-130000.00%
Revenue Growth (YoY)
-69.99%
Profit Growth (YoY)
-69.99%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.59
PE Ratio (TTM)
-
Forward PE
16.58
PS Ratio (TTM)
1435.97
PB Ratio
3.86
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-130000.00%
Revenue Growth (YoY)
-69.99%
Profit Growth (YoY)
-69.99%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is INO's latest earnings report released?

    The most recent financial report for Inovio pharmaceuticals, inc. (INO) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating INO's short-term business performance and financial health. For the latest updates on INO's earnings releases, visit this page regularly.

  • How is INO's revenue growth?

    In the latest financial report, Inovio pharmaceuticals, inc. (INO) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does INO have?

    As of the end of the reporting period, Inovio pharmaceuticals, inc. (INO) had total debt of 9.37M, with a debt ratio of 0.13. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does INO have?

    At the end of the period, Inovio pharmaceuticals, inc. (INO) held Total Cash and Cash Equivalents of 44.27M, accounting for 0.6 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does INO go with three margins increasing?

    In the latest report, Inovio pharmaceuticals, inc. (INO) did not achieve the “three margins increasing” benchmark, with a gross margin of -1,035.04%%, operating margin of 26,745.94%%, and net margin of -5,761.72%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess INO's profit trajectory and future growth potential.

  • Is INO's EPS continuing to grow?

    According to the past four quarterly reports, Inovio pharmaceuticals, inc. (INO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.31. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of INO?

    Inovio pharmaceuticals, inc. (INO)'s Free Cash Flow (FCF) for the period is -19.5M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 0.54% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of INO?

    The latest valuation data shows Inovio pharmaceuticals, inc. (INO) has a Price-To-Earnings (PE) ratio of -1.37 and a Price/Earnings-To-Growth (PEG) ratio of -0.51. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.